ADCIRCA® (tadalafil)
Behind you all the way.
When you prescribe ADCIRCA, United Therapeutics Cares is there to support what comes next. From initiating benefits investigations to coordinating prescriptions and providing ongoing patient education, our team helps support your patients so they can focus on what matters.
Enroll a patient
Prescribe and help enroll your patient in support.
Learn more about prescribing ADCIRCA on the product website, or reach out to 1‑800‑545‑5979 to ask about completing the referral form.
Visit sitePrescribing and enrollment resources
These resources can help with the getting started process.
-
Request for support form
Secure access
Navigate access with confidence.
Our team works with you to help your patients secure and maintain access to their prescription. We’ll keep you up to date throughout the process, pull in our Therapy Access Managers as needed, and provide educational resources for your office at each stage.
Benefits investigations
We will initiate the benefits investigation process and assist patients with navigating access and affordability challenges that may arise.
Benefits investigations
We will initiate the benefits investigation process and assist patients with navigating access and affordability challenges that may arise.
Prior authorizations
Certain medications may require prior authorization. These requirements vary by health plan or pharmacy benefit manager (PBM), but we’ll share materials that can help educate you through the submission process and keep you informed of your patient’s status.
Prior authorizations
Certain medications may require prior authorization. These requirements vary by health plan or pharmacy benefit manager (PBM), but we’ll share materials that can help educate you through the submission process and keep you informed of your patient’s status.
Denials and appeals
If your patient’s coverage is denied, we can provide education on next steps regarding the appeal process and the information needed by the insurer.
Denials and appeals
If your patient’s coverage is denied, we can provide education on next steps regarding the appeal process and the information needed by the insurer.
Access resources
Find resources to support prior authorization, along with sample letters of medical necessity and appeals for your patients.
-
How Therapy Access Managers (TAMs) can help
-
Prior authorization checklist
-
ADCIRCA sample statement of medical necessity
-
ADCIRCA sample appeal letter
-
See all resources
View all
Find financial support
Help your patient explore financial support options.
Cost is a common concern for patients. Depending on their situation, a range of financial assistance options may be available for eligible patients. We can put them in touch with our Access & Affordability Specialists to walk them through what they may qualify for.
Co-pay assistance
If your patient has a commercial insurance plan, our co-pay assistance program can help cover out-of-pocket expenses. Visit our co-pay website to learn more about how eligible patients can pay as little as a $0 co-pay per prescription for ADCIRCA. The United Therapeutics Cares Co-Pay Assistance Program will pay the difference up to a monthly maximum program benefit.*
Visit co-pay site *Patients must meet certain eligibility criteria to qualify for assistance.Co-pay assistance
If your patient has a commercial insurance plan, our co-pay assistance program can help cover out-of-pocket expenses. Visit our co-pay website to learn more about how eligible patients can pay as little as a $0 co-pay per prescription for ADCIRCA. The United Therapeutics Cares Co-Pay Assistance Program will pay the difference up to a monthly maximum program benefit.*
Visit co-pay site *Patients must meet certain eligibility criteria to qualify for assistance.Additional financial resources
Our commitment to your patients’ care goes beyond our program’s support and education. If their situation requires more assistance, explore additional options through RE Assist, an online tool for finding healthcare financial support.
Visit RE AssistAdditional financial resources
Our commitment to your patients’ care goes beyond our program’s support and education. If their situation requires more assistance, explore additional options through RE Assist, an online tool for finding healthcare financial support.
Visit RE Assist“The most common worry I hear is…how much is this going to cost, and how can I afford this?”

See what your patients can expect from our program.
Learn morePlease see below for Important Safety Information
CONTRAINDICATIONS
- Nitrates and Guanylate Cyclase (GC) Stimulators: Do not use ADCIRCA in patients taking medicines that contain nitrates or guanylate cyclase stimulators (such as riociguat), as the combination could cause a sudden, unsafe drop in blood pressure. Do not use nitrates within 48 hours of the last dose of ADCIRCA.
- Hypersensitivity Reactions: Patients with a known serious hypersensitivity to tadalafil should not take ADCIRCA
Important Safety Information for ADCIRCA® (tadalafil) tablets
CONTRAINDICATIONS
- Nitrates and Guanylate Cyclase (GC) Stimulators: Do not use ADCIRCA in patients taking medicines that contain nitrates or guanylate cyclase stimulators (such as riociguat), as the combination could cause a sudden, unsafe drop in blood pressure. Do not use nitrates within 48 hours of the last dose of ADCIRCA.
- Hypersensitivity Reactions: Patients with a known serious hypersensitivity to tadalafil should not take ADCIRCA
WARNINGS AND PRECAUTIONS
- Cardiovascular: Patients who experience anginal chest pain after taking ADCIRCA should seek immediate medical attention
- Hypotension: Phosphodiesterase 5 inhibitors (PDE-5is), including tadalafil, have mild systemic vasodilatory properties that may result in transient decreases in blood pressure. Before prescribing ADCIRCA, carefully consider whether patients with underlying cardiovascular disease could be adversely affected by such actions.
- Worsening Pulmonary Vascular Occlusive Disease: Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of ADCIRCA to these patients is not recommended
- Vision/Hearing: Patients who experience a sudden loss of vision in one or both eyes, which could be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), or sudden decrease or loss of hearing after taking ADCIRCA should seek immediate medical attention
- Prolonged Erection: In rare instances, men taking PDE-5is (including tadalafil) for ED reported an erection lasting more than four hours. Male patients who experience a prolonged erection should seek immediate medical attention
SPECIAL POPULATIONS AND POTENTIAL DRUG INTERACTIONS:
- Special Populations (Pregnant or Expecting Pregnancy): Limited data from case series with tadalafil use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Pregnant women with untreated pulmonary arterial hypertension are at risk for heart failure, stroke, preterm delivery, and maternal and fetal death.
- Special Populations (Renal or Hepatic Impairment): The use of ADCIRCA is not recommended for patients with severe renal or hepatic impairment. Please see Full Prescribing Information for dosing recommendations for patients with mild to moderate renal or hepatic impairment
- Potential Drug Interactions: The use of ADCIRCA with alpha blockers, blood pressure medications, or alcohol may lower blood pressure significantly and may lead to symptomatic hypotension (light-headedness or fainting)
- Potential Drug Interactions: Tadalafil is metabolized predominately by CYP3A in the liver. Use of ADCIRCA with potent CYP3A inhibitors, such as ketoconazole and itraconazole, should be avoided. For patients on ADCIRCA therapy that require treatment with ritonavir, ADCIRCA should be discontinued at least 24 hours prior to starting ritonavir. For patients on ritonavir therapy that require treatment with ADCIRCA, start ADCIRCA at 20 mg once a day. Use of ADCIRCA with potent inducers of CYP3A, such as rifampin, should be avoided
- Potential Drug Interactions: ADCIRCA contains the same ingredient (tadalafil) as Cialis®, which is used to treat erectile dysfunction (ED) and the signs and symptoms of benign prostatic hyperplasia (BPH). The safety and efficacy of combinations of ADCIRCA with Cialis or other PDE-5is have not been studied. Therefore, the use of such combinations is not recommended
ADVERSE REACTIONS
- Adverse Reactions: The most common adverse event with ADCIRCA is headache (42% ADCIRCA vs 15% placebo). Other common adverse events (reported by ≥9% of patients on ADCIRCA and more frequent than placebo by 2%) include myalgia (14% vs 4%), nasopharyngitis (13% vs 7%), flushing (13% vs 2%), respiratory tract infection (13% vs 6%), extremity pain (11% vs 2%), nausea (11% vs 6%), back pain (10% vs 6%), dyspepsia (10% vs 2%), and nasal congestion (9% vs 1%)
ADC.ISI.HCP.SEP2020
For more information about ADCIRCA, please see the
Full Prescribing Information
and
Patient Information
or call 1-800-545-5979.







